CD19 and diffuse large B-cell lymphoma: The Fc‐enhanced CD19 monoclonal antibody tafasitamab plus lenalidomide resulted in an ORR of 60% with a 43% CR rate in patients with R/R DLBCL ineligible for ASCT [38].